Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies

Neuromuscular Disorders

Volumn 24, Issue 3, 2014, Pages 227-240

  Bachinski, Linda L ^a   Baggerly, Keith A ^a   Neubauer, Valerie L ^a   Nixon, Tamara J ^a   Raheem, Olayinka ^b   Sirito, Mario ^a   Unruh, Anna K ^a   Zhang, Jiexin ^a   Nagarajan, Lalitha ^a   Timchenko, Lubov T ^c   Bassez, Guillaume ^d   Eymard, Bruno ^e   Gamez, Josep ^f   Ashizawa, Tetsuo ^g   Mendell, Jerry R ^h   Udd, Bjarne ^a,i,j   Krahe, Ralf ^a,k  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d HENRI MONDOR HOSPITAL   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g UNIVERSITY OF FLORIDA   (United States)

^h THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

^j Vasa Central Hospital   (Finland)

^k UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

Aberrant isoform expression; DM1; DM2; Missplicing; Myotonic dystrophy

Indexed keywords

ABERRANT ISOFORM EXPRESSION; DM1; DM2; MISSPLICING; MYOTONIC DYSTROPHY;

ADULT; AGED; AGED, 80 AND OVER; CHILD; EXONS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MYOTONIC DISORDERS; MYOTONIC DYSTROPHY; PROTEIN ISOFORMS; RNA SPLICING; YOUNG ADULT;

EID: 84894238416     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2013.11.001     Document Type: Article

References (69)

1. Harper P.S. Myotonic dystrophy 1989, W.B. Saunders Co, London, UK. 2nd ed.
2. Udd B., Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 2012, 11:891-905.
3. Brook J.D., McCurrach M.E., Harley H.G., et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992, 68:799-808.
4. Fu Y.H., Pizzuti A., Fenwick R.G., et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992, 255:1256-1258.
5. Mahadevan M., Tsilfidis C., Sabourin L., et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992, 255:1253-1255.
6. Liquori C.L., Ricker K., Moseley M.L., et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001, 293:864-867.
7. Bachinski L.L., Udd B., Meola G., et al. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet 2003, 73:835-848.
8. Amack J.D., Mahadevan M.S. The myotonic dystrophy expanded CUG repeat tract is necessary but not sufficient to disrupt C2C12 myoblast differentiation. Hum Mol Genet 2001, 10:1879-1887.
9. Mankodi A., Logigian E., Callahan L., et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 2000, 289:1769-1773.
10. Cooper T.A. Molecular biology. Neutralizing toxic RNA. Science 2009, 325:272-273.
11. La Spada A.R., Taylor J.P. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat Rev Genet 2010, 11:247-258.
12. Osborne R.J., Thornton C.A. RNA-dominant diseases. Hum Mol Genet 2006, 15(Spec No 2):R162-R169.
13. Wheeler T.M., Thornton C.A. Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol 2007, 20:572-576.
14. Lin X., Miller J.W., Mankodi A., et al. Failure of MBNL1-dependent postnatal splicing transitions in myotonic dystrophy. Hum Mol Genet 2006, 15:2087-2097.
15. Kalsotra A., Xiao X., Ward A.J., et al. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci USA 2008, 105:20333-20338.
16. Du H., Cline M.S., Osborne R.J., et al. Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol 2010, 17:187-193.
17. Wang E.T., Cody N.A., Jog S., et al. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell 2012, 150:710-724.
18. Charlet-B N., Savkur R.S., Singh G., Philips A.V., Grice E.A., Cooper T.A. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 2002, 10:45-53.
19. Lueck J.D., Lungu C., Mankodi A., et al. Chloride channelopathy in myotonic dystrophy resulting from loss of posttranscriptional regulation for CLCN1. Am J Physiol Cell Physiol 2007, 292:C1291-1297.
20. Lueck J.D., Mankodi A., Swanson M.S., Thornton C.A., Dirksen R.T. Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol 2007, 129:79-94.
21. Mankodi A., Takahashi M.P., Jiang H., et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 2002, 10:35-44.
22. Wheeler T.M., Lueck J.D., Swanson M.S., Dirksen R.T., Thornton C.A. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 2007, 117:3952-3957.
23. Kanadia R.N., Johnstone K.A., Mankodi A., et al. A muscleblind knockout model for myotonic dystrophy. Science 2003, 302:1978-1980.
24. Mahadevan M.S., Yadava R.S., Yu Q., et al. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet 2006, 38:1066-1070.
25. Timchenko N.A., Patel R., Iakova P., Cai Z.J., Quan L., Timchenko L.T. Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis. J Biol Chem 2004, 279:13129-13139.
26. Gomes-Pereira M., Cooper T.A., Gourdon G. Myotonic dystrophy mouse models: towards rational therapy development. Trends Mol Med 2011, 17:506-517.
27. Sicot G., Gourdon G., Gomes-Pereira M. Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges. Hum Mol Genet 2011, 20:R116-123.
28. Bachinski L.L., Sirito M., Bohme M., Baggerly K.A., Udd B., Krahe R. Altered MEF2 isoforms in myotonic dystrophy and other neuromuscular disorders. Muscle Nerve 2010, 42:856-863.
29. Orengo J.P., Ward A.J., Cooper T.A. Alternative splicing dysregulation secondary to skeletal muscle regeneration. Ann Neurol 2011, 69:681-690.
30. Sallinen R., Vihola A., Bachinski L.L., et al. New methods for molecular diagnosis and demonstration of the (CCTG)n mutation in myotonic dystrophy type 2 (DM2). Neuromuscul Disord 2004, 14:274-283.
31. Cheung H.C., Baggerly K.A., Tsavachidis S., et al. Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays. BMC Genomics 2008, 9:216.
32. Udd B., Meola G., Krahe R., et al. Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies: 140th ENMC International Workshop with guidelines on management 2006, Neuromuscul Disord.
33. Vihola A., Bachinski L.L., Sirito M., et al. Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2. Acta Neuropathol 2010, 119:465-479.
34. Krol J., Fiszer A., Mykowska A., Sobczak K., de Mezer M., Krzyzosiak W.J. Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. Mol Cell 2007, 25:575-586.
35. Batra R., Charizanis K., Swanson M.S. Partners in crime: bidirectional transcription in unstable microsatellite disease. Hum Mol Genet 2010, 19:R77-82.
36. Osborne R.J., Lin X., Welle S., et al. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet 2009, 18:1471-1481.
37. Orengo J.P., Chambon P., Metzger D., Mosier D.R., Snipes G.J., Cooper T.A. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci USA 2008, 105:2646-2651.
38. Jiang H., Mankodi A., Swanson M.S., Moxley R.T., Thornton C.A. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet 2004, 13:3079-3088.
39. 2+-ATPase in myotonic dystrophy type 1. Hum Mol Genet 2005, 14:2189-2200.
40. Nakamori M., Kimura T., Fujimura H., Takahashi M.P., Sakoda S. Altered mRNA splicing of dystrophin in type 1 myotonic dystrophy. Muscle Nerve 2007, 36:251-257.
41. Nakamori M., Kimura T., Kubota T., et al. Aberrantly spliced alpha-dystrobrevin alters alpha-syntrophin binding in myotonic dystrophy type 1. Neurology 2008, 70:677-685.
42. Savkur R.S., Philips A.V., Cooper T.A. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001, 29:40-47.
43. Sergeant N., Sablonniere B., Schraen-Maschke S., et al. Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet 2001, 10:2143-2155.
44. Buj-Bello A., Furling D., Tronchere H., et al. Muscle-specific alternative splicing of myotubularin-related 1 gene is impaired in DM1 muscle cells. Hum Mol Genet 2002, 11:2297-2307.
45. Philips A.V., Timchenko L.T., Cooper T.A. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 1998, 280:737-741.
46. Raheem O., Olufemi S.E., Bachinski L.L., et al. Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2. Am J Pathol 2010, 177:3025-3036.
47. Schneider-Gold C., Timchenko L.T. CCUG repeats reduce the rate of global protein synthesis in myotonic dystrophy type 2. Rev Neurosci 2010, 21:19-28.
48. Zhang Y., Ye J., Chen D., et al. Differential expression profiling between the relative normal and dystrophic muscle tissues from the same LGMD patient. J Transl Med 2006, 4:53.
49. Clark T.A., Schweitzer A.C., Chen T.X., et al. Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol 2007, 8:R64.
50. Ha K., Coulombe-Huntington J., Majewski J. Comparison of Affymetrix Gene Array with the Exon Array shows potential application for detection of transcript isoform variation. BMC Genomics 2009, 10:519.
51. Izaguirre D.I., Zhu W., Hai T., Cheung H.C., Krahe R., Cote G.J. PTBP1-dependent regulation of USP5 alternative RNA splicing plays a role in glioblastoma tumorigenesis. Mol Carcinogenesis 2012, 51:895-906.
52. Cheung H.C., Hai T., Zhu W., et al. Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines. Brain 2009, 132:2277-2288.
53. Hu J., He X., Cote G.J., Krahe R. Singular Value Decomposition-based Alternative Splicing Detection. J Am Stat Assoc 2009, 104:944-953.
54. de la Grange P., Gratadou L., Delord M., Dutertre M., Auboeuf D. Splicing factor and exon profiling across human tissues. Nucl Acids Res 2010, 38:2825-2838.
55. Menghi F., Jacques T.S., Barenco M., et al. Genome-wide analysis of alternative splicing in medulloblastoma identifies splicing patterns characteristic of normal cerebellar development. Cancer Res 2011, 71:2045-2055.
56. Kong S.W., Hu Y.W., Ho J.W., et al. Heart failure-associated changes in RNA splicing of sarcomere genes. Circ Cardiovasc Genet 2010, 3:138-146.
57. Yamashita Y., Matsuura T., Shinmi J., et al. Four parameters increase the sensitivity and specificity of the exon array analysis and disclose 25 novel aberrantly spliced exons in myotonic dystrophy 2012, J Hum Genet.
58. Castro P., Liang H., Liang J.C., Nagarajan L. A novel, evolutionarily conserved gene family with putative sequence-specific single-stranded DNA-binding activity. Genomics 2002, 80:78-85.
59. Xu Z., Meng X., Cai Y., Liang H., Nagarajan L., Brandt S.J. Single-stranded DNA-binding proteins regulate the abundance of LIM domain and LIM domain-binding proteins. Genes Dev 2007, 21:942-955.
60. Gungor C., Taniguchi-Ishigaki N., Ma H., et al. Proteasomal selection of multiprotein complexes recruited by LIM homeodomain transcription factors. Proc Natl Acad Sci USA 2007, 104:15000-15005.
61. Cai Y., Xu Z., Nagarajan L., Brandt S.J. Single-stranded DNA-binding proteins regulate the abundance and function of the LIM-homeodomain transcription factor LHX2 in pituitary cells. Biochem Biophys Res Commun 2008, 373:303-308.
62. Wang Y., Klumpp S., Amin H.M., et al. SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability. Oncogene 2010, 29:3044-3053.
63. Hashimoto Y., Muramatsu K., Kunii M., et al. Uncovering genes required for neuronal morphology by morphology-based gene trap screening with a revertible retrovirus vector. FASEB J 2012, 26:4662-4674.
64. Romashkova J.A., Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401:86-90.
65. Ho T.H., Bundman D., Armstrong D.L., Cooper T.A. Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum Mol Genet 2005, 14:1539-1547.
66. Vicente-Crespo M., Pascual M., Fernandez-Costa J.M., et al. Drosophila muscleblind is involved in troponin T alternative splicing and apoptosis. PLoS One 2008, 3:e1613.
67. Kalsotra A., Cooper T.A. Functional consequences of developmentally regulated alternative splicing. Nat Rev Genet 2011, 12:715-729.
68. Koebis M., Ohsawa N., Kino Y., Sasagawa N., Nishino I., Ishiura S. Alternative splicing of myomesin 1 gene is aberrantly regulated in myotonic dystrophy type 1. Genes Cells 2011, 16:961-972.
69. Raghavachari N., Barb J., Yang Y., et al. A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease. BMC Med Genomics 2012, 5:28.